Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The burden of atopic dermatitis (AD) was assessed. A population-based, cross-sectional questionnaire study was performed among 34,313 Swedish adults in 2017. The prevalence of AD was 14%. Adults with mild AD had an increased relative risk ratio (RRR) of severe depression (aRRR 1.78, 95% confidence interval (95% CI) 1.50-2.12) and anxiety (aRRR 1.97, 95% CI 1.69-2.30), which was higher for severe AD (aRRR 6.22 95% CI 4.60- 8.42, aRRR 5.62 95% CI 4.10-7.71, respectively). Persons with severe AD were less likely to have a university degree (aRRR 0.55, 95% CI 0.34-0.90) and more likely to have a lower annual income (238,000-324,000 SEK: aRRR 0.51, 95% CI 0.39-0.77; 325,000 SEK or more 0.36; 0.25-0.58) compared with individuals without AD. These results suggest that AD implies an increased prevalence of comorbid mental conditions and an adverse impact on academic achievement and work. These adverse associations increase substantially for patients with severe AD and comorbid asthma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2340/00015555-3257 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The role of the Hippo pathway in allergic diseases: Mechanisms and therapeutic potential.
Int Immunopharmacol
September 2025
Clinical Research Center, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi 214023, China. Electronic address:
Allergic diseases, characterized by complex pathological mechanisms involving immune dysregulation and chronic inflammation, impose a substantial burden on global health. The Hippo signaling pathway, a highly conserved regulator of cell proliferation, apoptosis, immune homeostasis, and tissue repair, has recently emerged as a pivotal player in allergic disease pathogenesis. This review synthesizes current knowledge on the core components and physiological functions of the Hippo pathway, elucidates its mechanistic roles in major allergic disorders-including allergic asthma, allergic rhinitis, atopic dermatitis, and food allergies-and evaluates the therapeutic potential of targeting this pathway.
View Article and Find Full Text PDFEarly preschool wheeze trajectories are predominantly non-allergic with distinct biologic and microbiome traits.
J Allergy Clin Immunol
September 2025
Department of Pediatrics, and Translational Medicine, SickKids Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada. Electronic address:
Background: Disentangling preschool wheezing heterogeneity in terms of clinical traits, temporal patterns, and collective healthcare burden is critical for precise and effective interventions.
Objective: We aimed to collectively define contributions and distinct characteristics of respiratory phenotypes based on longitudinal wheeze and atopic sensitization patterns in the first 5 years of life.
Methods: Group-based trajectory analysis was performed in the CHILD Cohort study to identify distinct wheeze and allergic sensitization trajectories.
Atopic dermatitis, hypertension, and cardiovascular risk: an appraisal of the evidence.
Ital J Dermatol Venerol
September 2025
Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark.
Atopic dermatitis is the most common chronically or chronically relapsing inflammatory skin disease, characterized by intense pruritus, eczematous lesions, and a significant disease burden. Emerging evidence in recent years suggests that atopic dermatitis and the associated chronic systemic inflammation have health implications beyond the skin. For psoriasis, another chronic inflammatory skin disease, the association with cardiovascular diseases (CVDs) is well-established.
View Article and Find Full Text PDFNetwork Meta-analysis of 1.5% Ruxolitinib Cream Versus Systemic Agents in the Treatment of Moderate Atopic Dermatitis.
Dermatol Ther (Heidelb)
September 2025
Incyte Biosciences Canada Corporation, Pointe-Claire, QC, Canada.
Introduction: Atopic dermatitis (AD) is a chronic, highly pruritic, relapsing inflammatory disease associated with high quality-of-life burden. Topical 1.5% ruxolitinib cream is a selective Janus kinase (JAK)1/JAK2 inhibitor that is well tolerated and effective in improving itch and lesion clearance in patients ≥ 12 years old.
View Article and Find Full Text PDFDupilumab for the treatment of cutaneous graft-versus-host disease: a systematic review and individual patient data meta-analysis.
Transplant Cell Ther
August 2025
Division of Pediatric Oncology/Hematology, Bone marrow transplant Unit, Meyer Children's Hospital IRCCS, Florence, Italy; Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, Florence, Italy.
Background: Graft-versus-host disease (GvHD) remains a challenging complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT), especially in steroid-refractory cases. Dupilumab, a monoclonal antibody targeting IL-4Rα and inhibiting Th2-mediated inflammation, has recently emerged as a potential off-label treatment for cutaneous GvHD with atopic dermatitis (AD)-like features. However, comprehensive evidence on its use in this setting is limited.
View Article and Find Full Text PDF